Lior Shaltiel
Amministratore Delegato presso NUREXONE BIOLOGIC INC.
Patrimonio netto: 158 950 $ in data 31/05/2024
Profilo
Dr. Lior Shaltiel is a Chief Executive Officer & Director at NurExone Biologic Ltd.
and a Chief Executive Officer & Director at NurExone Biologic, Inc. He is on the Board of Directors at NurExone Biologic Ltd.
and NurExone Biologic, Inc.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC
0.63% | 16/05/2024 | 425 000 ( 0.63% ) | 158 950 $ | 31/05/2024 |
Posizioni attive di Lior Shaltiel
| Società | Posizione | Inizio |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Amministratore Delegato | 01/04/2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Amministratore Delegato | 01/04/2021 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NUREXONE BIOLOGIC INC. | Health Technology |
| Aziende private | 1 |
|---|---|
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
- Borsa valori
- Insiders
- Lior Shaltiel
